Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.

Kazuki TanakaNaoki InuiMasato KarayamaHideki YasuiHironao HozumiYuzo SuzukiKazuki FuruhashiTomoyuki FujisawaNoriyuki EnomotoYutaro NakamuraHideki KusagayaShun MatsuuraTomohiro UtoDai HashimotoTakashi MatsuiKazuhiro AsadaTakafumi Suda

Published in: Cancer chemotherapy and pharmacology (2019)

Adding olanzapine to antiemetic therapy with aprepitant, a 5-HT3 receptor antagonist and dexamethasone improved CINV control in patients receiving carboplatin-containing chemotherapy.

Keyphrases

chemotherapy induced
phase ii study
high glucose
diabetic rats
low dose
phase iii
high dose
drug induced
locally advanced
oxidative stress
open label
randomized controlled trial
squamous cell carcinoma
mesenchymal stem cells
radiation therapy
cell therapy
stress induced
placebo controlled